Financing physiocrines

aTyr Pharma Inc. could have raised more in its series D round last week, but decided to cap the financing at $49 million and instead take out a $10 million loan. The $59 million should give the company enough runway to demonstrate clinical proof of concept for its lead physiocrine program to treat rare